All News
Is exercise the missing medicine in lupus?
For lupus, sedentary lifestyle may be a driving force of disease activity. Today, the final day of ACR, Sarah Patterson, MD from UCSF will present
Read Article
#L01 #acr22 @rheumnow chronic GC use in rheum Dx assoctd w/⬇️ T scores & ⬆️fracture even if dose 2.5 mg or less. GC use ≥5 mg/day associated w/ 2-fold higher risk of fracture of any kind compared to all other doses& controls (aHR 2.37, 95% CI 1.33-4.23).Preventable w/anti-OP Rx https://t.co/sCWkEBPMMT
Olga Petryna DrPetryna ( View Tweet)
Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC
Richard Conway RichardPAConway ( View Tweet)
Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW
Richard Conway RichardPAConway ( View Tweet)
Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z
Richard Conway RichardPAConway ( View Tweet)
Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3
Richard Conway RichardPAConway ( View Tweet)
Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD-IR RA. Improve DAS28-CRP, CDAI, SDAI, TJC, SJC at day 113. @RheumNow #ACR22 Abstr#2008 https://t.co/RwRbeFC4rt https://t.co/F8bEI1lZGM
Richard Conway RichardPAConway ( View Tweet)
L09 #ACR22 MTX in Post-Roe Era
6% patients reported barrier to MTX access
1 pt noted restriction to HCQ
Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason
Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts
@RheumNow https://t.co/8Yr7nynzN6
Eric Dein ericdeinmd ( View Tweet)
L10 #ACR22 Efgartigimod in IMNM
IgG1 Fc fragment targeting neonatal Fc receptor (FcRn)
Restored grip and muscle strength in mice studies with pathogenic anti-HMGCR+ (p<0.05)
Total IgG and anti-HMGCR Ab became undetectable
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p
Richard Conway RichardPAConway ( View Tweet)
Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW
Richard Conway RichardPAConway ( View Tweet)
Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr
Richard Conway RichardPAConway ( View Tweet)
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2
Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure.
AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%)
@RheumNow https://t.co/G31PrfqtVu
Eric Dein ericdeinmd ( View Tweet)
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS
P3b: SEC 150 mg v SEC 300 v SDZ-ADL
Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance
Hard to assess as overall, low rate of progression
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Lindegren et al. Dairy intake and RA risk in Sweden. Nested case-control. High regular milk intake assoc increased risk (OR 1.90) High cheese assoc decresaed risk (OR 0.52) @RheumNow #ACR22 Abstr#1758 https://t.co/jUz3SJBf4Y https://t.co/ZykW3NjSrK
Richard Conway RichardPAConway ( View Tweet)
A spicy result. say NO to turmeric in #rheumatoidarthritis Eat it on food, but don’t expect it to help your joints. @RheumNow #ACR22 https://t.co/1mZBm3rYAA
Janet Pope Janetbirdope ( View Tweet)
Utamawatin et al. DB-RCT of Triamcinolone 10mg vs 40mg for knee OA. No difference! Wonder if 10mg would be better than saline? @RheumNow #ACR22 Abstr#1890 https://t.co/vcKze7mSf4 https://t.co/ErEkmUN0Wp
Richard Conway RichardPAConway ( View Tweet)
Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in variants that are more prominent ex Omicron strains. But should we use in high risk Pts ex long rituximab users? I do in this group. @RheumNow #ACR22 https://t.co/A8soYbg9ZD
Janet Pope Janetbirdope ( View Tweet)
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz
Richard Conway RichardPAConway ( View Tweet)
Does tofacitinib work better in patients with PsA and AS who smoke?
Abstract #1036 #ACR22 @RheumNow
🚬519 ever smokers
🚭767 never smokers
💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO
✋Overall, efficacy was generally comparable in ever v. never 🚬
Catherine Sims, MD DrCassySims ( View Tweet)